VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01541280 |
|
Recruitment Status :
Completed
First Posted : February 29, 2012
Last Update Posted : March 18, 2016
|
Sponsor:
Nantes University Hospital
Information provided by (Responsible Party):
Nantes University Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | July 2015 |
| Actual Study Completion Date : | July 2015 |